Astellas Pharma Balance Sheet Health
Financial Health criteria checks 4/6
Astellas Pharma has a total shareholder equity of ¥1,529.8B and total debt of ¥935.8B, which brings its debt-to-equity ratio to 61.2%. Its total assets and total liabilities are ¥3,462.2B and ¥1,932.4B respectively. Astellas Pharma's EBIT is ¥170.0B making its interest coverage ratio 38.6. It has cash and short-term investments of ¥293.0B.
Key information
61.2%
Debt to equity ratio
JP¥935.83b
Debt
| Interest coverage ratio | 38.6x |
| Cash | JP¥292.99b |
| Equity | JP¥1.53t |
| Total liabilities | JP¥1.93t |
| Total assets | JP¥3.46t |
Recent financial health updates
Recent updates
Astellas Pharma (TSE:4503) Has Announced A Dividend Of ¥37.00
Jan 03
Astellas Pharma (TSE:4503) Will Pay A Dividend Of ¥37.00
Dec 04Astellas Pharma's (TSE:4503) Earnings May Just Be The Starting Point
Nov 06Astellas Pharma Inc. (TSE:4503) Just Released Its Half-Yearly Earnings: Here's What Analysts Think
Nov 01Astellas Pharma Inc.'s (TSE:4503) Earnings Haven't Escaped The Attention Of Investors
Oct 15Astellas Pharma (TSE:4503) Has Announced That It Will Be Increasing Its Dividend To ¥37.00
Sep 24Astellas Pharma (TSE:4503) Has Announced That It Will Be Increasing Its Dividend To ¥37.00
Sep 03Astellas Pharma (TSE:4503) Has Announced That It Will Be Increasing Its Dividend To ¥37.00
Aug 20Earnings Beat: Astellas Pharma Inc. Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Models
Aug 04Astellas Pharma's (TSE:4503) Shareholders Will Receive A Bigger Dividend Than Last Year
Jul 26Astellas Pharma (TSE:4503) Is Paying Out A Larger Dividend Than Last Year
Jul 11Is Astellas Pharma (TSE:4503) A Risky Investment?
Jun 14Astellas Pharma's (TSE:4503) Soft Earnings Are Actually Better Than They Appear
May 02Astellas Pharma Inc. Earnings Missed Analyst Estimates: Here's What Analysts Are Forecasting Now
Apr 29Why We're Not Concerned About Astellas Pharma Inc.'s (TSE:4503) Share Price
Feb 29Financial Position Analysis
Short Term Liabilities: 4503's short term assets (¥1,203.0B) exceed its short term liabilities (¥1,093.4B).
Long Term Liabilities: 4503's short term assets (¥1,203.0B) exceed its long term liabilities (¥839.0B).
Debt to Equity History and Analysis
Debt Level: 4503's net debt to equity ratio (42%) is considered high.
Reducing Debt: 4503's debt to equity ratio has increased from 0.2% to 61.2% over the past 5 years.
Debt Coverage: 4503's debt is well covered by operating cash flow (21.5%).
Interest Coverage: 4503's interest payments on its debt are well covered by EBIT (38.6x coverage).
Balance Sheet
Discover healthy companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/01/08 21:06 |
| End of Day Share Price | 2025/01/08 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2024/03/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Astellas Pharma Inc. is covered by 31 analysts. 16 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Atsushi Seki | Barclays |
| Koichi Mamegano | BofA Global Research |
| Hazim Bahari | CFRA Equity Research |